FDA FENFLURAMINE/REDUX EPIDEMIOLOGICAL ANALYSIS OF HMO RECORDS SUPPORTS FINDINGS OF VALVULOPATHY IN ASYMPTOMATIC PATIENTS REPORTED FROM FIVE SURVEYS

An FDA analysis of computerized patient records from an Oregon HMO provided one piece of evidence that convinced the agency to recommend that Wyeth-Ayerst withdraw Redux (dexfenfluramine) and Pondimin (fenfluramine) from the market.